On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

  • Chung‐Feng Huang
    Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
  • Tyng‐Yuan Jang
    Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
  • Dae Won Jun
    Department of Internal Medicine Hanyang University Hospital Hanyang University College of Medicine Seoul South Korea
  • Sang Bong Ahn
    Department of Internal Medicine Nowon Eulji Medical Center Eulji University College of Medicine Seoul South Korea
  • Jihyun An
    Department of Internal Medicine Hanyang University Guri Hospital Hanyang University College of Medicine Guri South Korea
  • Masaru Enomoto
    Department of Hepatology Osaka City University Graduate School of Medicine Osaka Japan
  • Hirokazu Takahashi
    Liver Center Saga University Hospital Saga Japan
  • Eiichi Ogawa
    Department of General Internal Medicine Kyushu University Fukuoka Japan
  • Eileen Yoon
    Department of Internal Medicine Hanyang University Hospital Hanyang University College of Medicine Seoul South Korea
  • Soung Won Jeong
    Department of Internal Medicine Soonchunhyang University Hospital Soonchunhyang University College of Medicine Seoul South Korea
  • Jae‐Jun Shim
    Department of Internal Medicine Kyung Hee University Hospital Kyung Hee University School of Medicine Seoul South Korea
  • Jae Yoon Jeong
    Department of Internal Medicine Hanyang University Guri Hospital Hanyang University College of Medicine Guri South Korea
  • Sung Eun Kim
    Department of Internal Medicine Hallym University Sacred Heart Hospital Hallym University College of Medicine Anyan South Korea
  • Hyunwoo Oh
    Department of Internal Medicine Uijeongbu Eulji Medical Center Eulji University School of Medicine Uijeongbu South Korea
  • Hyoung Su Kim
    Department of Internal Medicine Hallym University Kangdong Sacred Heart Hospital Hallym University College of Medicine Seoul South Korea
  • Yong Kyun Cho
    Department of Internal Medicine Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine Seoul South Korea
  • Ritsuzo Kozuka
    Department of Hepatology Osaka City University Graduate School of Medicine Osaka Japan
  • Kaori Inoue
    Liver Center Saga University Hospital Saga Japan
  • Ka Shing Cheung
    Department of Medicine The University of Hong Kong Hong Kong Hong Kong
  • Lung Yi Mak
    Department of Medicine The University of Hong Kong Hong Kong Hong Kong
  • Jee‐Fu Huang
    Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
  • Chia‐Yen Dai
    Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan
  • Man‐Fung Yuen
    Department of Medicine The University of Hong Kong Hong Kong Hong Kong
  • Mindie H. Nguyen
    Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
  • Ming‐Lung Yu
    Hepatobiliary Division Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Medical University Kaohsiung Taiwan

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background & Aims</jats:title><jats:p>Gamma‐glutamyl transferase (GGT) has been predictive of chronic hepatitis C‐related hepatocellular carcinoma (HCC) development. Its role in the risk of HCC in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues (NAs) is elusive.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 2172 CHB patients from East Asia were randomized into development and validation groups in a 1:2 ratio. Serum GGT levels before and 6 months (M6) after initiating NAs and the potential risk factors were measured. The primary endpoint was HCC development 12 months after NA initiation.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The annual incidence of HCC was 1.4/100 person‐years in a follow‐up period of 11 370.7 person‐years. The strongest factor associated with HCC development was high M6‐GGT levels (>25 U/L; hazard ratio [HR]/95% confidence interval [CI]: 3.31/2.02‐5.42, <jats:italic>P</jats:italic> < .001), followed by cirrhosis (HR/CI: 2.06/1.39‐3.06, <jats:italic>P</jats:italic> < .001), male sex (HR/CI: 2.01/1.29‐3.13, <jats:italic>P</jats:italic> = .002) and age (HR/CI: 1.05/1.03‐1.17, <jats:italic>P</jats:italic> < .001). Among cirrhotic patients, the incidence of HCC did not differ between those with high or low M6‐GGT levels (<jats:italic>P</jats:italic> = .09). In contrast, among non‐cirrhotic patients, the incidence of HCC was significantly higher for those with M6‐GGT level >25 U/L than for their counterparts (<jats:italic>P</jats:italic> < .001). Cox regression analysis revealed that the strongest factor associated with HCC development in non‐cirrhotic patients was high M6‐GGT levels (HR/CI: 5.05/2.52‐10.16, <jats:italic>P</jats:italic> < .001), followed by age (HR/CI: 1.07/1.04‐1.09, <jats:italic>P</jats:italic> < .001). Non‐cirrhotic elderly patients with high M6‐GGT levels had a similarly high HCC risk as cirrhotic patients did (<jats:italic>P</jats:italic> = .29).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>On‐treatment serum GGT levels strongly predicted HCC development in CHB patients, particularly non‐cirrhotic patients, treated with NAs.</jats:p></jats:sec>

収録刊行物

参考文献 (41)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ